Kun‐Chieh Chen

1.7k total citations
48 papers, 1.1k citations indexed

About

Kun‐Chieh Chen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Kun‐Chieh Chen has authored 48 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 36 papers in Oncology and 12 papers in Cancer Research. Recurrent topics in Kun‐Chieh Chen's work include Lung Cancer Treatments and Mutations (36 papers), Lung Cancer Research Studies (20 papers) and Colorectal Cancer Treatments and Studies (10 papers). Kun‐Chieh Chen is often cited by papers focused on Lung Cancer Treatments and Mutations (36 papers), Lung Cancer Research Studies (20 papers) and Colorectal Cancer Treatments and Studies (10 papers). Kun‐Chieh Chen collaborates with scholars based in Taiwan, United States and United Kingdom. Kun‐Chieh Chen's co-authors include Tsung‐Ying Yang, Gee‐Chen Chang, Kuo-Hsuan Hsu, Jeng‐Sen Tseng, Sung‐Liang Yu, Kang‐Yi Su, Yen-Hsiang Huang, Shih‐Lan Hsu, Jeremy J.W. Chen and Chun‐Chi Wu and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Kun‐Chieh Chen

47 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kun‐Chieh Chen Taiwan 22 603 602 333 215 69 48 1.1k
Jingjing Xie China 22 301 0.5× 385 0.6× 470 1.4× 197 0.9× 37 0.5× 39 1.2k
Ravi Thakur India 18 214 0.4× 202 0.3× 466 1.4× 107 0.5× 19 0.3× 36 1.2k
Hsiang‐i Tsai China 16 192 0.3× 165 0.3× 537 1.6× 215 1.0× 49 0.7× 32 964
Zhendong Zheng China 19 137 0.2× 203 0.3× 377 1.1× 184 0.9× 14 0.2× 82 867
Huanrong Lan China 22 160 0.3× 448 0.7× 474 1.4× 254 1.2× 12 0.2× 62 1.1k
Shijie Li China 16 246 0.4× 329 0.5× 488 1.5× 184 0.9× 7 0.1× 55 1.1k
Yujie Zhao China 16 427 0.7× 357 0.6× 386 1.2× 204 0.9× 6 0.1× 67 1.1k
Hongyang Lu China 18 375 0.6× 453 0.8× 242 0.7× 106 0.5× 6 0.1× 84 888
Anna M. Azarova United States 8 132 0.2× 502 0.8× 743 2.2× 86 0.4× 21 0.3× 9 1.2k
Qianqian Yu China 21 92 0.2× 218 0.4× 552 1.7× 98 0.5× 40 0.6× 37 1.0k

Countries citing papers authored by Kun‐Chieh Chen

Since Specialization
Citations

This map shows the geographic impact of Kun‐Chieh Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kun‐Chieh Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kun‐Chieh Chen more than expected).

Fields of papers citing papers by Kun‐Chieh Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kun‐Chieh Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kun‐Chieh Chen. The network helps show where Kun‐Chieh Chen may publish in the future.

Co-authorship network of co-authors of Kun‐Chieh Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Kun‐Chieh Chen. A scholar is included among the top collaborators of Kun‐Chieh Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kun‐Chieh Chen. Kun‐Chieh Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chiang, Chun‐Ju, Kun‐Chieh Chen, Sung‐Liang Yu, et al.. (2024). Taiwan Nationwide Study of First-Line ALK–TKI Therapy in ALK-Positive Lung Adenocarcinoma. Targeted Oncology. 19(6). 941–955.
2.
Tseng, Jeng‐Sen, Kun‐Chieh Chen, Mong‐Wei Lin, et al.. (2024). Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib. Therapeutic Advances in Medical Oncology. 16. 2665342–2665342. 1 indexed citations
3.
Huang, Yen-Hsiang, Jeng‐Sen Tseng, Kuo-Hsuan Hsu, et al.. (2022). Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation. Medicine. 101(24). e29381–e29381. 3 indexed citations
4.
Huang, Yen-Hsiang, Kuo-Hsuan Hsu, Jeng‐Sen Tseng, et al.. (2022). The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan. Targeted Oncology. 17(3). 295–306. 8 indexed citations
5.
Su, Sheng‐Fang, Chia-Hsin Liu, Chao‐Chi Ho, et al.. (2021). Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses. JCO Precision Oncology. 5(5). 418–431. 14 indexed citations
6.
Huang, Yen-Hsiang, Kuo-Hsuan Hsu, Jeng‐Sen Tseng, et al.. (2021). The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma. Cancer Research and Treatment. 54(2). 434–444. 12 indexed citations
7.
Huang, Yen-Hsiang, Jeng‐Sen Tseng, Kuo-Hsuan Hsu, et al.. (2021). The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. Scientific Reports. 11(1). 12084–12084. 13 indexed citations
8.
Tseng, Jeng‐Sen, Kuo-Hsuan Hsu, Tsung‐Ying Yang, et al.. (2020). Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment. Oncology. 99(1). 32–40. 9 indexed citations
9.
Chang, Gee‐Chen, Tsung‐Ying Yang, Kun‐Chieh Chen, et al.. (2020). ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients. Scientific Reports. 10(1). 21063–21063. 31 indexed citations
10.
Su, Kang‐Yi, Jeng‐Sen Tseng, Tsung‐Ying Yang, et al.. (2018). Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma. PLoS ONE. 13(11). e0207001–e0207001. 20 indexed citations
11.
Huang, Yen-Hsiang, Kuo-Hsuan Hsu, Jeng‐Sen Tseng, et al.. (2018). The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma. Cancer Research and Treatment. 50(4). 1294–1303. 46 indexed citations
12.
Chen, Kun‐Chieh. (2016). Generalized Approach for Selecting Plasma Chemistries in Metal Etch. eScholarship (California Digital Library). 2 indexed citations
13.
Chen, Yu‐Lun, Tsung‐Ying Yang, Kun‐Chieh Chen, et al.. (2016). Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers. Cellular Oncology. 39(5). 411–433. 41 indexed citations
14.
Tseng, Jeng‐Sen, Chih‐Liang Wang, Ming‐Shyan Huang, et al.. (2014). Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma. PLoS ONE. 9(9). e107160–e107160. 11 indexed citations
15.
Chen, Chiu-Yuan, et al.. (2013). Gallic Acid Induces a Reactive Oxygen Species-Provoked c-Jun NH2-Terminal Kinase-Dependent Apoptosis in Lung Fibroblasts. Evidence-based Complementary and Alternative Medicine. 2013. 1–12. 26 indexed citations
16.
17.
Tseng, Jeng‐Sen, Tsung‐Ying Yang, Kun‐Chieh Chen, et al.. (2012). Retrospective study of erlotinib in patients with advanced squamous lung cancer. Lung Cancer. 77(1). 128–133. 32 indexed citations
18.
Chang, Gee‐Chen, Chun‐Ming Tsai, Kun‐Chieh Chen, et al.. (2006). Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology. 1(6). 520–525. 32 indexed citations
19.
20.
Chang, Gee‐Chen, et al.. (2004). Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status. Investigational New Drugs. 23(1). 73–77. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jingjing Xie Breakdown of academic impact, for papers by Ravi Thakur Breakdown of academic impact, for papers by Hsiang‐i Tsai Breakdown of academic impact, for papers by Zhendong Zheng Breakdown of academic impact, for papers by Huanrong Lan Breakdown of academic impact, for papers by Shijie Li Breakdown of academic impact, for papers by Yujie Zhao Breakdown of academic impact, for papers by Hongyang Lu Breakdown of academic impact, for papers by Anna M. Azarova Breakdown of academic impact, for papers by Qianqian Yu
Rankless by CCL
2026